Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys”) today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding development plans for two Phase III clinical trials of sparsentan in Japan (development code: RE-021) – one investigating the use of sparsentan in focal segmental glomerulosclerosis (FSGS) and the […]